 Craig-Hallum initiated coverage of iSpecimen Inc NASDAQ:ISPC with a Buy rating and 20 price target. Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods, the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt. 